Hindustan Laboratories IPO Description – Hindustan Laboratories is a pharmaceutical player focused on the development, manufacturing, and supply of generic formulations, primarily catering to government institutions under a B2G (business-to-government) model. Its products are supplied through central and state government tenders, enabling large-scale distribution across 27 states and union territories.
The company operates a diversified portfolio of acute and chronic therapeutic segments such as vitamins, blood-related treatments, anti-infectives, cardiac care, gastrointestinal, and pain management. As of September 2025, the product portfolio expanded to 948 formulations from 661 in FY23. Notably, key segments like vitamins, blood-related, antiparasitic, and analgesics together contributed over 60% of revenues, indicating a strong presence in high-demand categories. The company has an integrated manufacturing facility in Palghar with over 900 approved formulations and WHO-GMP certification. As of 30 September 2025, the company has a workforce of 284 employees and 332 contract labourers.
Promoters of Hindustan Laboratories – Rajesh Vasantray Doshi, Kunjal C Dedhia, Krishiv Rajesh Doshi
Hindustan Laboratories IPO Details
| Hindustan Laboratories IPO Dates | Coming soon |
| Hindustan Laboratories Issue Price | Coming soon |
| Fresh Issue | 50,00,000 shares |
| Offer For Sale | 91,00,000 shares |
| Total IPO Size | 1,41,00,000 shares |
| Minimum Bid (Lot Size) | Coming soon |
| Pre-issue Shares | *** shares |
| Face Value | INR 10 per share |
| Listing On | NSE, BSE |
Hindustan Laboratories IPO Allocation in Different Categories
Hindustan Laboratories Financial Performance
| FY 2023 | FY 2024 | FY 2025 | H1 FY 2026 | |
| Revenue | 172.34 | 186.37 | 219.75 | 112.63 |
| Expenses | 149.72 | 148.25 | 172.26 | 91.13 |
| Net Income | 22.25 | 34.18 | 41.27 | 18.24 |
| Margin (%) | 12.91 | 18.34 | 18.78 | 16.19 |
Hindustan Laboratories Offer News
Hindustan Laboratories Valuations & Margins
| FY 2023 | FY 2024 | FY 2025 (Pre-Issue) | FY 2026* (Post-Issue) | |
| EPS | 4.46 | 6.85 | 8.28 | – |
| PE Ratio | – | – | – | – |
| Price/Sales Ratio | – | – | – | – |
| Price/Book Ratio | – | – | – | – |
| Current Ratio | 3.15 | 3.86 | 4.50 | – |
| FY 2023 | FY 2024 | FY 2025 | |
| RONW (%) | 24.18 | 28.39 | 26.11 |
| NAV | 20.69 | 27.54 | 35.85 |
| ROCE (%) | 31.76 | 37.25 | 33.13 |
| EBITDA (%) | 17.81 | 23.66 | 24.52 |
| Debt/Equity | 0.01 | 0.08 | 0.06 |
Evaluate the quality of an IPO using these essential investing ratios to make an informed decision.
Hindustan Laboratories IPO Anchor Investors
Hindustan Laboratories raises () from anchor investors. Hindustan Laboratories Anchor bid date is ().
| Bid Date | Coming soon |
| Shares Offered | Coming soon |
| Anchor Portion (INR Cr.) | Coming soon |
| Anchor lock-in period end date for 50% shares (30 Days) | Coming soon |
| Anchor lock-in period end date for remaining shares (90 Days) | Coming soon |
Hindustan Laboratories IPO GMP Today (Daily Trend)
Hindustan Laboratories Offer Objectives
The company proposes to utilize net proceeds from the issue towards the following objects:
- Funding the working capital requirements of the company – INR 72.5 crore
- General Corporate Purposes
Hindustan Laboratories IPO Subscription – Live Updates
Coming soon
() shares allotted to anchor investors are not included in these calculations.
Hindustan Laboratories – Comparison With Listed Peers
| Company | PE ratio | EPS | RONW (%) | NAV | Revenue (Cr.) |
| Hindustan Laboratories | – | 8.28 | 26.11 | 35.85 | 227.37 |
| Ajanta Pharma | 35.25 | 73.56 | 25.02 | 301.59 | 777.90 |
| Syncom Formulations (India) | 25.70 | 0.57 | 15.69 | 3.64 | 482.45 |
| Windlas Biotech | 25.70 | 29.19 | 12.76 | 243.18 | 4,742.60 |
Hindustan Laboratories IPO Allotment Status
You can check Hindustan Laboratories IPO allotment status on MUFG Intime’s website. Click on this link to get the allotment status. Often not getting IPO allotment? Learn how to improve your IPO allotment chances.
Hindustan Laboratories IPO Dates & Listing Performance
| IPO Opening Date | Coming soon |
| IPO Closing Date | Coming soon |
| Finalization of Basis of Allotment | Coming soon |
| Initiation of refunds | Coming soon |
| Transfer of shares to demat accounts | Coming soon |
| Hindustan Laboratories IPO Listing Date | Coming soon |
| Opening Price on NSE | Coming soon |
| Closing Price on NSE | Coming soon |
Hindustan Laboratories IPO Reviews – Subscribe or Avoid?
Angel One –
Anand Rathi –
Axis Capital –
Antique Stock Broking –
Arihant Capital –
Ashika Research –
Asit C Mehta –
BP Wealth –
Capital Market –
Canara Bank Securities –
Choice Broking –
Dalal & Broacha –
Elite Wealth –
GCL Broking –
Geojit –
GEPL Capital –
Hem Securities –
ICICIdirect –
Investmentz –
Jainam Broking –
DR Choksey –
LKP Research –
Marwadi Financial –
Motilal Oswal –
Nirmal Bang –
Reliance Securities –
SBI Securities –
Samco Securities –
SMC Global –
Swastika Investmart –
Ventura Securities –
Hindustan Laboratories IPO Lead Manager
CHOICE CAPITAL ADVISORS PRIVATE LIMITED
Sunil Patodia Tower, Plot No. 156-158 J.B. Nagar,
Andheri (East), Mumbai – 400 099, Maharashtra
Phone: +91 226707 9999 /7919
Email: [email protected]
Website: www.choiceindia.com
Hindustan Laboratories Offer Registrar
MUFG INTIME (LINK INTIME) INDIA PRIVATE LIMITED
C-101, 1st Floor, 247 Park L.B.S. Marg,
Vikhroli West, Mumbai – 400 083, Maharashtra
Telephone: +91 810 811 4949
Email: [email protected]
Website: www.in.mpms.mufg.com
HINDUSTAN LABORATORIES LIMITED
301, 303, 304, and 305, A Wing,
Victory Park, Chandavarkar Road,
Borivali West, Mumbai – 400092, Maharashtra
Phone: 022-42460500
Email: [email protected]
Website: www.hindustanlaboratories.com
IPO Resources
How many shares in Hindustan Laboratories IPO are reserved for HNIs and retail investors?
The investors’ portion for QIB – 50%, NII – 15%, and Retail – 35%.
How to apply in Hindustan Laboratories Public Offer?
What is Hindustan Laboratories IPO GMP today?
Hindustan Laboratories IPO GMP today is INR NA per share.
What is Hindustan Laboratories Subject to Sauda rate today?
Hindustan Laboratories Subject to Sauda rate today is INR NA per application.
Krishna comes from a family of investors and financial analysts, She learnt wading through regulatory filings pretty early in her career. She has several years of experience in financial and industry analysis under her belt. At IPO Central, Krishna plays twin roles of Contributor and Head of research desk.
